B+
Bull case
25%
Probability
Target price
$20.40
+18.6% vs current
AMRX
AmnealANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$18.25
+6.1% vs current
B-
Bear case
25%
Probability
Target price
$15.17
-11.8% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+46.9
Score
AI commentary
The operating evidence is constructive but forward visibility remains limited. Q1 results and the Kashiv announcement provide positive company-specific support, while the July 30 earnings date is the next clear checkpoint. Recent-news, analyst-revision, options, short-interest, and social coverage are insufficient for a stronger sentiment call.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-30catalystQ2 2026 results will test affirmed full-year guidanceMedium impact
Amneal scheduled its Q2 2026 results for July 30, 2026. The update should test Specialty and complex-generic momentum against the affirmed FY2026 revenue, EBITDA, EPS, and cash-flow outlook. [#PR-EARNINGS-2026-07-09] [#SEC-8K-2026-05-07]
2026-12-31eventKashiv acquisition closing and integrationHigh impact
Amneal agreed to acquire Kashiv using cash and equity consideration, with additional potential regulatory milestone payments and royalties. A clean close and credible integration could strengthen the biosimilars growth narrative, while execution and financing remain key risks. [#SEC-8K-2026-04-22]
2027-12-31catalystBiosimilar platform expansion and launch cadenceHigh impact
The Kashiv transaction is intended to create a scaled, integrated biosimilars platform with development, manufacturing, and pipeline capabilities. Longer-term value depends on approvals, launches, commercialization, and integration execution. [#SEC-8K-2026-04-22]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology